Emerging drugs for dementia with Lewy Bodies: a review of Phase II &amp; III trials

Tolea, Magdalena I.; Ezzeddine, Reem; Camacho, Simone; Galvin, James E.

doi:10.1080/14728214.2023.2244425

Cited by 6 publications

(1 citation statement)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improvement in diagnosis is crucial for optimizing patient care outcomes, particularly with the ongoing development of new therapeutic options ( 28 , 29 ). The relatively recent approval of 123 I-ioflupane for SPECT to assist with diagnosing DLB from AD warrants a closer examination of the role of DAT SPECT imaging in clinical practice and how it can help address current diagnostic challenges for DLB specifically.…”

Section: Introductionmentioning

confidence: 99%

Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions

O’Shea,

Arkhipenko,

Galasko

et al. 2024

Front. Neurol.

Self Cite

View full text Add to dashboard Cite

BackgroundDiagnosing Dementia with Lewy Bodies (DLB) remains a challenge in clinical practice. The use of 123I-ioflupane (DaTscan™) SPECT imaging, which detects reduced dopamine transporter (DAT) uptake—a key biomarker in DLB diagnosis—could improve diagnostic accuracy. However, DAT imaging is underutilized despite its potential, contributing to delays and suboptimal patient management.MethodsThis review evaluates DLB diagnostic practices and challenges faced within the U.S. by synthesizing information from current literature, consensus guidelines, expert opinions, and recent updates on DaTscan FDA filings. It contrasts DAT SPECT with alternative biomarkers, provides recommendations for when DAT SPECT imaging may be indicated and discusses the potential of emerging biomarkers in enhancing diagnostic approaches.ResultsThe radiopharmaceutical 123I-ioflupane for SPECT imaging was initially approved in Europe (2000) and later in the US (2011) for Parkinsonism/Essential Tremor. Its application was extended in 2022 to include the diagnosis of DLB. DaTscan’s diagnostic efficacy for DLB, with its sensitivity, specificity, and predictive values, confirms its clinical utility. However, US implementation faces challenges such as insurance barriers, costs, access issues, and regional availability disparities.Conclusion123I-ioflupane SPECT Imaging is indicated for DLB diagnosis and differential diagnosis of Alzheimer’s Disease, particularly in uncertain cases. Addressing diagnostic obstacles and enhancing physician-patient education could improve and expedite DLB diagnosis. Collaborative efforts among neurologists, geriatric psychiatrists, psychologists, and memory clinic staff are key to increasing diagnostic accuracy and care in DLB management.

show abstract

Section: Introductionmentioning

confidence: 99%